Yasir Gallero-Salas discusses quantifying alpha-synuclein spread and dopaminergic neuron loss in a model of Parkinson’s using ...
Nearly one million people in the U.S. are living with Parkinson’s disease (PD), and this number is expected to grow to 1.2 ...
BioArctic has dosed the first subject with the monoclonal antibody, exidavnemab, in the randomised Phase IIa EXIdavnemab ...
Funding has been made available which will enable new research to take place into a possible link between manganese exposure ...
The company is hoping to show GT-02287 can slow Parkinson's progression by restoring function of GCase, an enzyme encoded by ...
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
When Denver artist Tim McKay was diagnosed with Parkinson’s disease last year, he made a quick decision: He would document ...
BIIB122, previously known as DNL151, is a small molecule designed to inhibit LRRK2, mutations in which are the most common cause of inherited Parkinson's.
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson's disease patients. Exidavnemab is a ...
Wearable devices once seemed futuristic for Parkinson’s disease. Today, tools like activity trackers, tremor gloves, and ...